Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Titan Biotech
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 30.33 | 36.84 | 34.75 | 43.43 | 45.98 | 39.92 | 43.11 | 39.89 | 38.28 | 35.17 | 46.50 | 54.35 | 56.51 |
| Expenses + | 26.19 | 30.00 | 26.86 | 34.71 | 35.38 | 32.85 | 34.86 | 32.13 | 33.43 | 30.60 | 37.76 | 45.02 | 45.68 |
| Operating Profit | 4.14 | 6.84 | 7.89 | 8.72 | 10.60 | 7.07 | 8.25 | 7.76 | 4.85 | 4.57 | 8.74 | 9.33 | 10.83 |
| OPM % | 13.65% | 18.57% | 22.71% | 20.08% | 23.05% | 17.71% | 19.14% | 19.45% | 12.67% | 12.99% | 18.80% | 17.17% | 19.16% |
| Other Income + | 0.28 | 0.49 | 0.28 | 0.55 | 0.44 | 0.48 | 0.62 | 0.32 | 1.59 | 1.38 | 0.72 | 1.32 | 1.26 |
| Interest | 0.14 | 0.26 | 0.29 | 0.28 | 0.26 | 0.34 | 0.31 | 0.27 | 0.15 | 0.08 | 0.20 | 0.22 | 0.26 |
| Depreciation | 0.65 | 0.71 | 0.80 | 0.86 | 0.83 | 0.84 | 1.05 | 1.10 | 1.18 | 0.84 | 1.15 | 1.21 | 1.27 |
| Profit before tax | 3.63 | 6.36 | 7.08 | 8.13 | 9.95 | 6.37 | 7.51 | 6.71 | 5.11 | 5.03 | 8.11 | 9.22 | 10.56 |
| Tax % | 25.62% | 27.04% | 23.73% | 25.71% | 25.63% | 24.02% | 24.23% | 25.48% | 25.64% | 25.25% | 24.04% | 25.60% | 25.57% |
| Net Profit + | 3.26 | 4.95 | 6.16 | 6.52 | 7.17 | 5.00 | 6.40 | 6.70 | 4.39 | 4.05 | 6.86 | 7.76 | 8.53 |
| EPS in Rs | 0.79 | 1.20 | 1.49 | 1.58 | 1.74 | 1.21 | 1.55 | 1.62 | 1.06 | 0.98 | 1.66 | 1.88 | 2.07 |
Financials of Titan Biotech
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 40 | 46 | 53 | 57 | 65 | 79 | 142 | 124 | 144 | 164 | 156 | 193 |
| Expenses + | 36 | 42 | 47 | 50 | 56 | 66 | 96 | 92 | 114 | 130 | 131 | 159 |
| Operating Profit | 4 | 4 | 5 | 7 | 9 | 13 | 46 | 31 | 30 | 34 | 25 | 33 |
| OPM % | 10% | 9% | 10% | 12% | 14% | 17% | 32% | 25% | 21% | 21% | 16% | 17% |
| Other Income + | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 4 | 5 |
| Interest | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 4 |
| Profit before tax | 2 | 3 | 3 | 4 | 6 | 10 | 43 | 29 | 28 | 32 | 24 | 33 |
| Tax % | 33% | 34% | 35% | 35% | 30% | 25% | 26% | 25% | 25% | 25% | 25% | |
| Net Profit + | 2 | 2 | 2 | 3 | 4 | 8 | 32 | 22 | 25 | 25 | 22 | 27 |
| EPS in Rs | 0.42 | 0.46 | 0.56 | 0.66 | 0.85 | 1.71 | 7.35 | 5.25 | 6.01 | 6.02 | 5.21 | 6.59 |
| Dividend Payout % | 36% | 33% | 27% | 23% | 0% | 12% | 4% | 6% | 6% | 7% | 8% |
Financials of Titan Biotech
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 13 | 14 | 15 | 17 | 24 | 31 | 60 | 78 | 102 | 125 | 145 | 158 |
| Borrowings + | 8 | 11 | 22 | 26 | 24 | 24 | 16 | 9 | 9 | 8 | 3 | 9 |
| Other Liabilities + | 5 | 7 | 7 | 7 | 9 | 13 | 16 | 13 | 16 | 15 | 19 | 27 |
| Total Liabilities | 34 | 40 | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 202 |
| Fixed Assets + | 11 | 11 | 13 | 14 | 29 | 31 | 34 | 35 | 36 | 52 | 57 | 57 |
| CWIP | 1 | 5 | 9 | 13 | 0 | 0 | 0 | 4 | 13 | 3 | 2 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 15 | 28 | 33 | 48 |
| Other Assets + | 21 | 24 | 30 | 30 | 36 | 45 | 67 | 65 | 70 | 74 | 83 | 95 |
| Total Assets | 34 | 40 | 52 | 57 | 65 | 76 | 101 | 108 | 135 | 157 | 175 | 202 |
Financials of Titan Biotech
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -2 | 5 | 0 | 2 | 5 | 6 | 19 | 22 | 21 | 21 | 20 |
| Cash from Investing Activity + | -3 | -5 | -8 | -6 | -4 | -2 | -5 | -16 | -21 | -20 | -10 |
| Cash from Financing Activity + | 3 | 2 | 9 | 0 | -0 | -4 | -11 | -4 | -2 | -3 | -8 |
| Net Cash Flow | -2 | 2 | 1 | -3 | 1 | -0 | 4 | 2 | -2 | -2 | 2 |
| Free Cash Flow | -3 | 0 | -7 | -4 | 1 | 8 | 14 | 8 | 8 | 12 | 12 |
| CFO/OP | -28% | 143% | 21% | 43% | 74% | 62% | 65% | 93% | 97% | 85% | 103% |
Financials of Titan Biotech
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 47 | 44 | 49 | 52 | 54 | 46 | 48 | 53 | 42 | 44 |
| Inventory Days | 134 | 118 | 155 | 202 | 236 | 259 | 177 | 206 | 179 | 208 | 242 |
| Days Payable | 17 | 18 | 15 | 13 | 24 | 38 | 20 | 25 | 27 | 15 | 25 |
| Cash Conversion Cycle | 175 | 147 | 184 | 239 | 264 | 276 | 203 | 230 | 205 | 234 | 261 |
| Working Capital Days | 94 | 60 | 90 | 108 | 97 | 101 | 88 | 118 | 109 | 111 | 130 |
| ROCE % | 12% | 12% | 13% | 15% | 20% | 58% | 32% | 27% | 25% | 17% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…